For the Inventor, By the Inventor

Enter assignee name

Manchester, United Kingdom

Redx Pharma Limited

Calculating rank

USPTO Granted Patents = 27

% Expired Patents = 44.4

CIPO Patents = 2

EPO Patents = 12

Forward Citations = 74

Loading Chart...

Loading Chart...

39 inventors (with patents filed for the assignee):

Inder Bhamra (10 out of 11 patents)

Richard Testar (8 out of 9 patents)

Craig Donoghue (7 out of 7 patents)

4. Matilda Bingham (6 out of 7 patents)

5. David John Moody (6 out of 7 patents)

6. Jonathan William Wiffen (6 out of 6 patents)

7. Louise Sargent (4 out of 4 patents)

8. Derek Lindsay (4 out of 5 patents)

9. Clifford David Jones (4 out of 16 patents)

10. Michael Mathieson (3 out of 3 patents)

11. Peter Jackson (3 out of 4 patents)

12. Thomas Pesnot (3 out of 5 patents)

13. Peter Bunyard (3 out of 3 patents)

14. Gary Pitt (3 out of 3 patents)

15. Liam Byrne (3 out of 3 patents)

Core Competencies:

DDR1 Inhibitors

Rho-Associated Protein Kinase

Wnt Signaling Pathway

Antibacterial Compounds

Fused Bicyclic Compounds

Hedgehog Signaling Pathway

Rosuvastatin Derivatives

Triazolo-Pyrazines

Redox Drug Derivatives

Pyridine Derivatives

Statin Preparation

Heterocyclic Compounds

27 patents: Sort by Forward Citations

1. 12692247 - Phenyl- and pyridopyrazole derivatives as inhibitors of DDR1 (2026-07-28),

2. 12453734 - Modulators of rho-associated protein kinase (2025-10-28),

3. 12202826 - N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway (2025-01-21),

4. 11878020 - Modulators of Rho-associated protein kinase (2024-01-23),

5. 11643408 - N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway (2023-05-09),

6. 11497751 - Modulators of Rho-associated protein kinase (2022-11-15),

7. 11459326 - N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors (2022-10-04),

8. 10793562 - N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors (2020-10-06),

9. 10793560 - N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway (2020-10-06),

10. 10487093 - Heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their use as antibacterial compounds (2019-11-26),

11. 10385065 - Antibacterial compounds (2019-08-20),

12. 10202375 - N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors (2019-02-12),

13. 10183939 - Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers (2019-01-22),

14. 10047079 - N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway (2018-08-14),

15. 9850234 - Pyridine derivatives as soft rock inhibitors (2017-12-26),

Company Overview

Redx Pharma Limited, based in Manchester, specializes in the discovery and development of innovative drug candidates targeting unmet medical needs. The company focuses on areas such as oncology and anti-infectives, leveraging its expertise in medicinal chemistry and drug development. Redx Pharma aims to advance its proprietary compounds through various stages of clinical development, contributing to the pharmaceutical landscape with a commitment to improving patient outcomes and addressing critical health challenges.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

27 Patents

#10 in Manchester

#655 in United Kingdom

#24,034 in the World

Manchester, United Kingdom

Redx Pharma Limited

Forward Citations = 74

39 inventors:

Inder Bhamra (10 out of 11 patents)

Richard Testar (8 out of 9 patents)

Craig Donoghue (7 out of 7 patents)

4. Matilda Bingham (6 out of 7 patents)

5. David John Moody (6 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Redx Pharma Limited. Retrieved from https://idiyas.com/company/redx-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…